Impact of Comorbidities on Tumor Necrosis Factor Inhibitor Therapy in Psoriatic Arthritis: A Population-Based Cohort Study

2018 ◽  
Vol 70 (4) ◽  
pp. 592-599 ◽  
Author(s):  
Christine Ballegaard ◽  
Pil Højgaard ◽  
Lene Dreyer ◽  
René Cordtz ◽  
Tanja Schjødt Jørgensen ◽  
...  
Keyword(s):  
Cohort Study ◽  
Psoriatic Arthritis ◽  
Tumor Necrosis Factor ◽  
Tumor Necrosis ◽  
Tumor Necrosis Factor Inhibitor ◽  
Population Based ◽  
Inhibitor Therapy ◽  
Factor Inhibitor ◽  
Necrosis Factor

scholarly journals Switch rates and total cost associated with apremilast and biologics in biologic-naive patients with psoriatic arthritis

2021 ◽  
Author(s):  
David L Kaplan ◽  
Brian L Ung ◽  
Corey Pelletier ◽  
Chuka Udeze ◽  
Ibrahim Khilfeh ◽  
...  
Keyword(s):  
Psoriatic Arthritis ◽  
Tumor Necrosis Factor ◽  
Real World ◽  
Tumor Necrosis ◽  
Claims Data ◽  
Tumor Necrosis Factor Inhibitor ◽  
Total Cost ◽  
Factor Inhibitor ◽  
Treatment Data ◽  
Necrosis Factor

Aim: Real-world treatment data for psoriatic arthritis are limited. We evaluated switch rates, adherence, and costs for patients initiating apremilast versus tumor necrosis factor inhibitor (TNFi) and interleukin inhibitor (ILi) among biologic-naive psoriatic arthritis patients. Materials & methods: This retrospective analysis used IBM MarketScan claims data to assess treatment switches, adherence and costs. Results: Twelve-month switch rates were significantly lower for apremilast versus TNFi (15.5% vs 26.6%; p < 0.0001) and similar to ILi (15.5% vs 14.0%; p = 0.71). Apremilast initiators had lower total costs versus TNFi and ILi (US$39,854 vs US$57,243 and US$65,687; p < 0.05) and adherence was slightly lower versus TNFi and higher versus ILi. Conclusion: Biologic-naive apremilast initiators had lower switch rates versus TNFi initiators and lower total costs versus TNFi or ILi initiators.

scholarly journals Long-term follow-up of secondary amyloidosis patients treated with tumor necrosis factor inhibitor therapy

Medicine ◽  
2017 ◽  
Vol 96 (34) ◽  
pp. e7859 ◽  
Author(s):  
Sinem Nihal Esatoglu ◽  
Gulen Hatemi ◽  
Serdal Ugurlu ◽  
Aycan Gokturk ◽  
Koray Tascilar ◽  
...  
Keyword(s):  
Tumor Necrosis Factor ◽  
Tumor Necrosis ◽  
Tumor Necrosis Factor Inhibitor ◽  
Inhibitor Therapy ◽  
Secondary Amyloidosis ◽  
Factor Inhibitor ◽  
Long Term Follow Up ◽  
Necrosis Factor
Sign in / Sign up

Export Citation Format

Share Document